Range
- - -
Vol / Avg.
-/1.5M
Div / Yield
-
52 Wk
4.6 - 17.19
Mkt Cap
481.6M
Payout Ratio
-
Open
-
P/E
-
EPS
-0.53
Shares
70.5M
Outstanding
70.5M
Total Float
-
Benzinga - Jun 15, 2021, 7:06AM
Benzinga - Jun 11, 2021, 9:43AM
Benzinga - Jun 11, 2021, 7:05AM
Benzinga - May 25, 2021, 7:04AM
Benzinga - May 12, 2021, 12:32PM
Benzinga - May 6, 2021, 12:08PM
Benzinga - May 6, 2021, 7:36AM
Benzinga - Apr 22, 2021, 11:20AM
Benzinga - Apr 20, 2021, 7:08AM
Benzinga - Apr 1, 2021, 8:48AM
Benzinga - Mar 29, 2021, 8:09AM
Benzinga - Mar 10, 2021, 7:20AM
Benzinga - Mar 4, 2021, 7:17AM
Benzinga - Feb 10, 2021, 6:59AM
Benzinga - Feb 8, 2021, 4:22PM
Benzinga - Jan 29, 2021, 8:25AM
Benzinga - Jan 7, 2021, 6:21AM
load more
Sector: Health Care.Industry: Biotechnology
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises five programs: AUTO1, AUTO1/22, AUTO3, AUTO4 and AUTO6. The company operates in two geographic regions, the United Kingdom and the United States.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-05
REV
Q1 2021Est.ActualSurprise
EPS-0.600-0.530 0.0700
REV340.000K269.000K-71.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
AUTLAutolus Therapeutics1.17%481.6M

Autolus Therapeutics Frequently Asked Questions

Q

How do I buy Autolus Therapeutics (AUTL) stock?

A

You can purchase shares of Autolus Therapeutics (NASDAQ: AUTL) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Autolus Therapeutics's (AUTL) competitors?

A

Other companies in Autolus Therapeutics’s space includes: CytomX Therapeutics (NASDAQ:CTMX), OncoCyte (NASDAQ:OCX), Gritstone Bio (NASDAQ:GRTS), VistaGen Therapeutics (NASDAQ:VTGN) and Viking Therapeutics (NASDAQ:VKTX).

Q

What is the target price for Autolus Therapeutics (AUTL) stock?

A

The latest price target for Autolus Therapeutics (NASDAQ: AUTL) was reported by Needham on May 6, 2021. The analyst firm set a price target for 21.00 expecting AUTL to rise to within 12 months (a possible 207.47% upside). 8 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Autolus Therapeutics (AUTL)?

A

The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $6.83 last updated Wed Jun 23 2021 20:00:04 GMT+0000 (Coordinated Universal Time).

Q

Does Autolus Therapeutics (AUTL) pay a dividend?

A

There are no upcoming dividends for Autolus Therapeutics.

Q

When is Autolus Therapeutics (NASDAQ:AUTL) reporting earnings?

A
Autolus Therapeutics’s Q2 earnings are confirmed for after-market on August 5, 2021.
Q

Is Autolus Therapeutics (AUTL) going to split?

A

There is no upcoming split for Autolus Therapeutics.

Q

What sector and industry does Autolus Therapeutics (AUTL) operate in?

A

Autolus Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.